Calcineurin inhibitors block MHC-restricted antigen presentation in vivo

Journal of Immunology

Volumn 179, Issue 9, 2007, Pages 5711-5716

  Lee, Young Hee ^a   Lee, Young Ran ^a   Im, Sun A ^a   Park, Sun Im ^a   Kim, Ki Hyang ^a   Gerelchuluun, Turmunkh ^a   Song, Sukgil ^a   Kim, Kyungjae ^b   Lee, Chong Kil ^a  

^a Chungbuk National University   (South Korea)

^b Sahmyook University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN A; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MICROSPHERE; OVALBUMIN; PEPTIDE; TACROLIMUS; CALCINEURIN; CYCLOSPORIN; HISTOCOMPATIBILITY ANTIGEN;

ANIMAL EXPERIMENT; ANTIGEN PRESENTATION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ISOLATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG MECHANISM; IMMUNOSUPPRESSIVE TREATMENT; LYMPH NODE; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MALE; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; SPLEEN; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; IMMUNOLOGY; MACROPHAGE; METABOLISM;

ANIMALS; ANTIGEN PRESENTATION; CALCINEURIN; CYCLOSPORINE; DENDRITIC CELLS; HISTOCOMPATIBILITY ANTIGENS; MACROPHAGES; MALE; MICE; OVALBUMIN; T-LYMPHOCYTES, CYTOTOXIC; TACROLIMUS;

EID: 38449111857     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.179.9.5711     Document Type: Article

References (45)

1. Guermonprez, P., J. Valladeau, L. Zitvogel, C. Thery, and S. Amigorena. 2002. Antigen presentation and T cell stimulation by dendritic cells. Annu. Rev. Immunol. 20: 621-667.
2. Bevan, M. J. 1976. Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J. Exp. Med. 143: 1283-1288.
3. Huang, A. Y., P. Golumbek, M. Ahmadzadeh, E. Jaffee, D. Pardoll, and H. Levitsky. 1994. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264: 961-965.
4. Harding, C. V. 1995. Phagocytic processing of antigens for presentation by MHC molecules. Trends Cell Biol. 5: 105-109.
5. Sigal, L. J., S. Crotty, R. Andino, and K. L. Rock. 1999. Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen. Nature 398: 77-80.
6. Heath, W. R., and F. R. Carbone. 2001. Cross-presentation, dendritic cells, tolerance and immunity. Annu. Rev. Immunol. 19: 47-64.
7. + T cells mediate graft rejection via a distinct effector pathway. Nat. Immunol. 3: 844-851.
8. + T cells in vivo: the key to rational vaccine design. Annu. Rev. Immunol. 23: 651-682.
9. Friedman, J., and I. Weissman. 1991. Two cytoplasmic candidates for immunophilin action are revealed by affinity for a new cyclophilin: one in the presence and one in the absence of CsA. Cell 66: 799-806.
10. Liu, J., J. D. Farmer, Jr., W. S. Lane, J. Friedman, I. Weissman, and S. L. Schreiber. 1991. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 66: 807-815.
11. Sigal, N. H., and F. J. Dumont. 1992. Cyclosporin A, FK-506, and rapamycin: pharmacologic probes of lymphocyte signal transduction. Annu. Rev. Immunol. 10: 519-560.
12. Lee, Y. R., I. H. Yang, Y. H. Lee, S. A. Im, S. Song, H. Li, K. Han, K. Kim, S. K. Eo, and C. K. Lee. 2005. Cyclosporin A and tacrolimus, but not rapamycin, inhibit MHC-restricted antigen presentation pathways in dendritic cells. Blood 105: 3951-3955.
13. Karttunen, J., S. Sanderson, and N. Shastri. 1992. Detection of rare antigen-presenting cells by the lacZ T-cell activation assay suggests an expression cloning strategy for T-cell antigens. Proc. Natl. Acad. Sci. USA 89: 6020-6024.
14. Harding, C. V., D. S. Collins, O. Kanagawa, and E. R. Unanue. 1991. Liposome-encapsulated antigens engender lysosomal processing for class II MHC presentation and cytosolic processing for class I presentation. J. Immunol. 147: 2860-2863.
15. Shen, Z., G. Reznikoff, G. Dranoff, and K. L. Rock. 1997. Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. J. Immunol. 158: 2723-2730.
16. Coles, R. M., S. N. Mueller, W. R. Heath, F. R. Carbone, and A. G. Brooks. 2002. Progression of armed CTL from draining lymph node to spleen shortly after localized infection with Herpes simplex virus 1. J. Immunol. 168: 834-838.
17. Larsen, C. P., E. T. Elwood, D. Z. Alexander, S. C. Ritchie, R. Hendrix, C. Tucker-Burden, H. R. Cho, A. Aruffo, D. Hollenbaugh, P. S. Linsley, et al. 1996. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 381: 434-438.
18. Li, Y., X. C. Li, X. X. Zheng, A. D. Wells, L. A. Turka, and T. B. Strom. 1999. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat. Med. 5: 1298-1302.
19. Smiley, S. T., V. Csizmadia, W. Gao, L. A. Turka, and W. W. Hancock. 2000. Differential effects of cyclosporine A, methylprednisolone, mycophenolate, and rapamycin on CD154 induction and requirement for NFκB: implications for tolerance induction. Transplantation 70: 415-419.
20. Blaha, P., S. Bigenzahn, Z. Koporc, M. Schmid, F. Langer, E. Selzer, H. Bergmeister, F. Wrba, J. Kurtz, C. Kiss, et al. 2003. The influence of immunosuppressive drugs on tolerance induction through bone marrow transplantation with costimulation blockade. Blood 101: 2886-2893.
21. Kirk, A. D., L. C. Burkly, D. S. Batty, R. E. Baumgartner, J. D. Berning, K. Buchanan, J. H. Fechnerr, Jr., R. L. Germond, R. L. Kampen, N. B. Patterson, et al. 1999. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat. Med. 5: 686-693.
22. Sho, M., S. E. Sandner, N. Najafian, A. D. Salama, V. Dong, A. Yamada, K. Kishimoto, H. Harada, I. Schmitt, and M. H. Sayegh. 2002. New insights into the interactions between T cell costimulatory blockade and conventional immunosuppressive drugs. Annu. Surg. 236: 667-675.
23. Opelz, G. 1995. Efficacy of rejection prophylaxis with OKT3 in renal transplantation: collaborative transplant study. Transplantation 60: 1220-1224.
24. Calne, R., P. Friend, S. Moffatt, A. Bradley, G. Hale, J. Firth, J. Bradley, K. Smith, and H. Waldmann. 1998. Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet 351: 1701-1702.
25. Hong, J. C., and B. D. Kahan. 2001. A calcineurin antagonist-free induction strategy for immunosuppression in cadaveric kidney transplant recipients at risk for delayed graft function. Transplantation 71: 1320-1328.
26. Wells, A. D., X. C. Li, Y. Li, M. C. Walsh, X. X. Zheng, Z. Wu, G. Nunez, A. Tang, M. Sayegh, W. W. Hancock, et al. 1999. Requirement for T cell apoptosis in the induction of peripheral transplantation tolerance. Nat. Med. 5: 1303-1307.
27. Dai, Z., B. T. Konieczny, F. K. Baddoura, and F. G. Lakkis. 1999. Impaired alloantigen mediated T-cell apoptosis and failure to induce long term allograft survival in IL-2 deficient mice. J. Immunol. 161: 1659-1663.
28. Konieczny, B. T., Z. Dai, E. T. Elwood, S. Saleem, P. S. Linsley, F. K. Baddoura. C. P. Larsen, T. C. Peaeson, and F. G. Lakkis. 1998. IFN-γγ is critical for long-term allograft survival induced by the blocking the CD28 and CD40 ligand T-cell costimulation pathways. J. Immunol. 160: 2059-2064.
29. Wood, K. J., and S. Skaguchi. 2003. Regulatory T cells in transplantation tolerance. Nat. Rev. Immunol. 3: 199-210.
30. Zheng, X. X., A. Sanchez-Fueyo, M. Sho, C. Domenig, M. H. Sayegh, and T. B. Strom. 2003. Favorably tipping the balance between cytopathic and regulatory T cells to create transplantation tolerance. Immunity 19: 503-514.
31. + regulatory T cells. Blood 105: 4743-4748.
32. Kawai, M., H. Kitade, C. Mathieu, M. Waer, and J. Pirenne. 2005. Inhibitory and stimulatory effects of cyclosporine A on the development of regulatory T cells in vivo. Transplantation 79: 1073-1077.
33. + regulatory T cells in renal transplant recipients. Transplantation 82: 550-507.
34. + regulatory T cells. Blood 107: 1018-1023.
35. + regulatory T-cell function. J. Exp. Med. 196: 851-857.
36. + T cell suppressor function. Eur. J. Immunol. 34: 366-376.
37. Boussiotis, V. A., G. J. Freeman, J. G. Gribben, and L. M. Nadler. 1996. The role of B7-1/B7-2:CD28/CTLA-4 pathway in the prevention of anergy, induction of protective immunity and down-regulation of the immune response. Immunol. Rev. 153: 5-26.
38. Greenfield, E. A., K. A. Nguyen, and V. K. Kuchroo. 1998. CD28/B7 costimulation: a review. Crit. Rev. Immunol. 18: 389-418.
39. Linsley, P. S., P. M. Wallace, J. Johnson, M. G. Gibson, J. L. Greene, J. A. Ledbetter, C. Singh, and M. A. Tepper. 1992. Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science 257: 792-795.
40. Woltman, A. M., J. W. de Fijter, S. W. Kamerling, L. C. Paul, M. R. Daha, and C. van Kooten. 2000. The effects of calcineurin inhibitors and corticosteroids on the differentiation of human dendritic cells. Eur. J. Immunol. 30: 1807-1812.
41. Morelli, A. E., M. A. Antonysamy, T. Takayama, H. Hackstein, Z. Chen, S. Qian, N. B. Zurowski, and A. W. Thomson. 2000. Microchimerism, donor dendritic cells, and alloimmune reactivity in recipients of Flt3 ligand-mobilized hemopoietic cells: modulation by tacrolimus. J. Immunol. 165: 226-237.
42. + T cells toward Th2 responses. J. Leukocyte Biol. 68: 633-640.
43. Smyth, L. A., O. B. Herrera, D. Golshayan, G. Lombardi, and R. I. Lechler. 2006. A novel pathway of antigen presentation by dendritic and endothelial cells: implications for allorecognition and infectious diseases. Transplantation 82 (Suppl. 1): S15-S18.
44. Rock, K. L., and L. Shen. 2005. Cross-presentation: underlying mechanisms and role in immune surveillance. Immunol. Rev. 207: 166-183.
45. Porgador, A., J. W. Yewdell, Y. Deng, J. R. Bennink, and R. N. Germain. 1997. Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using monoclonal antibody. Immunity 6: 715-726.